Problems with ejaculation?

Problems with ejaculation?

Problems with ejaculation?

Ejaculation is the natural culmination of a sexual act on a man’s side, be it intercourse or masturbation. It’s the vehicle of pleasure that all of us men are looking for in sex, the ultimate goal of all courtship rituals and the imperative command of our instincts. There are many ways to achieve ejaculation, ways that we have learnt from necessity and out of curiosity.

However, not everything is as good as it looks. Sexual dysfunctions are more and more common in today’s world. There may be some truth to the statement that the rising number of psychological and physical dysfunctions are the price we’re paying for the lifestyles of urban sprawls and for the ongoing pollution of our planet. But regardless of how we got here, let’s discuss a certain sexual dysfunction called “delayed ejaculation”. The term refers to the inhibition of ejaculation, which is the unfortunate situation when a man cannot ejaculate for some reason or other.

The most common form of delayed ejaculation makes the man unable to ejaculate in the presence of the partner. If the man can ejaculate well enough alone, using self stimulation, then it stands to reason that the causes for this dysfunction are purely psychological. Most men suffering from this kind of hang-up either have deep religious backgrounds and have been taught that sex is sin or simply are not attracted enough to their partners. There are also cases when traumatic events have led to this dysfunction. Men who found out that their partners were having affairs or who have been caught themselves during illicit sex or masturbation may feel too traumatized to achieve ejaculation.

Other men, however, cannot achieve ejaculation while masturbating, despite the fact that they have normal sex lives with their partners. Some of the causes mentioned above also apply in this case, especially being caught masturbating or being hampered by a religious background. Most religions consider masturbation to be sinful and wasting and teach their members that such practice is to be avoided. Some go to great lengths to discourage masturbation and other forms of sex.

In such cases willpower is not enough to force the body to feel something that isn’t there and it’s not a good idea to force yourself anyway. It might work once or twice, but that’s about as far as this approach will take you. It’s far better to seek professional help than to suffer in silence. Therapists can suggest a way out of the problem by discussing the situation at length with both partners.

The basic idea of the treatment is to teach the two partners about sexual stimulation and response in order to help them understand their own needs. Instead of using willpower to force the mind, the partners should focus on their ability to create an intimate setting that would provide ideal stimulation and so solve the problem.

Men can certainly use this approach on their own, although the risk of failure is significant. There are little tricks everybody can use to bring sex closer to an ideal situation. Relaxation always helps, which means that candle-lit rooms, romantic dinners, a bit of alcohol and perhaps some porn could prove very helpful, if both partners agree on this approach. Avoid delicate issues in conversation and focus on having fun in a relaxed way. Hug and caress instead of rushing to the sex part and be sure to take your time.

Another thing that might help is to train your pubococcygeus muscle and bring it under your control. Being able to relax and tense that muscle at will is likely to help in some cases. The Penis Health exercises program features a series of very good exercises designed to train the PC muscle.

Check the online pharmacy viagra Health Website for More Information

Breakthrough: Non-Interferon/Ribavirin Regimen Can Cure Hep C

April 4, 2011

by Tim Horn



In what is being heralded as a hepatitis C virus (HCV) treatment research breakthrough, a clinical trial evaluating two oral medications being developed by Bristol-Myers Squibb (BMS) suggests that at least some cases of chronic HCV infection can be cured without the use of either pegylated interferon or ribavirin (IFN/RBV).



The same study, reported Saturday, April 2, at the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, also appeared to cure 10 people living with HCV treated with a quadruple regimen, consisting of BMS’s BMS-650032 and BMS-790052 in combination with IFN/RBV.



Though a combination of IFN/RBV has long been the standard treatment for chronic HCV infection, both drugs are associated with side effects and neither drug works directly against the virus. The high rate of toxicities, compounded by their indirect mechanisms of action, help explain why current treatment isn’t highly effective in a proportion of people living with HCV, particularly those with hard-to-treat genotype 1 infection.



Direct-acting antivirals (DAAs), drugs that directly target HCV, have been in development for several years. Not only can they potentially maximize treatment responses and reduce the amount of time someone needs to be treated for HCV, but they also have been eyed as a way of treating hepatitis C without the need for either IFN or RBV.



Numerous studies at EASL suggest that DAAs, including protease inhibitors, NS5A inhibitors and polymerase inhibitors, can substantially increase rates of sustained virologic responses (SVRs)—maintaining an undetectable HCV viral load for six months after stopping treatment, or a viral cure—when used in combination with IFN/RBV. Not only did a clinical trial evaluating BMS’s protease purchase cialis (BMS-790052) and NS5A cialis (650032) add to the encouraging news, but it also demonstrated that two DAAs used together, without IFN/RBV, can cure HCV in some patients.



The Phase II study looked at a cohort of 21 HCV genotype 1 null responders—patients who had very limited responses to previous treatment with IFN/RBV—of whom 19 had an unfavorable IL28B genotype, which predisposes HCV patients to treatment failure. The cohort was divided into two groups: Group A involved 11 patients treated with BMS-790052 plus BMS-650032 without IFN/RB for 24 weeks; Group B involved 10 patients treated with both BMS drugs plus IFN/RBV for 24 weeks.



Nine of the 10 patients treated with quadruple therapy had an SVR after 24 weeks (SVR24), reported Anna Lok, MD, of the University of Michigan Medical Center at Ann Arbor and her colleagues. The one patient who didn’t have an SVR24 was tested again 35 days later and found to have an undetectable HCV viral load, suggesting a possible cure rate of 100 percent in the small number of individuals who received four-drug treatment.



Of particular interest are the results among those treated with the DAAs without IFN/RBV. Four of the 11 patients had an SVR24—among the first individuals in a clinical trial to be successfully cured of HCV without today’s standard-of-care drugs.



In the six patients who saw their HCV viral loads rebound during treatment with the DAAs, IFN/RBV was promptly added. Four of the patients then went on to achieve undetectable HCV viral loads. HCV resistance to both BMS-790052 and BMS-650032 was documented in all six patients who did not respond favorably to DAA therapy alone, though it is not clear what the implications of resistance are for those who potentially require retreatment with these or similar agents.



Many side effects were similar in both groups, including diarrhea, fatigue, headache, fever and difficulty sleeping. Most side effects, however, were mild to moderate in severity, and there were no discontinuations from the study due to adverse events. Moderate-to-severe drops in neutrophils, a type of white blood cell, was documented in six patients in the quadruple-therapy group, compared with no patients in the dual-DAA group.



Lok concluded that quadruple therapy can result in a high rate of cure in this difficult-to-treat population and that, based on the encouraging dual-DAA study results, that HCV infection can be cured without IFN or RBV.



Source



Also See:

EASL: Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment